GRAL Share Price Performance
US$43.03
-2.27 (-5.01%)
62.4% undervalued intrinsic discount
US$114.50
Fair Value
Price US$43.03
AnalystConsensusTarget US$114.50
AnalystHighTarget US$130.00
Fair ValueUS$114.50
Share Pricen/a
GRAIL, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
GRAL Community Narratives
AN
Fair Value US$114.5 62.4% undervalued intrinsic discount
GRAL: Execution Risks Remain High Amid PATHFINDER 2 Progress And Regulatory Shifts
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value US$130 66.9% undervalued intrinsic discount
NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening Adoption
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening Adoption
Catalysts About GRAIL GRAIL develops and commercializes Galleri, a blood based multi cancer early detection test aimed at finding cancers at earlier stages. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$130
66.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
32.58% p.a.
Profit Margin
15.7%
Future PE
146.51x
Price in 2029
US$159.68
GRAL: Execution Risks Remain High Amid PATHFINDER 2 Progress And Regulatory Shifts
Key Takeaways Positive clinical results and expanding commercial adoption of Galleri position GRAIL for strong regulatory momentum, payer support, and accelerated, diversified revenue growth. Enhanced process scalability and disciplined cost control are improving margins and reducing losses, while global partnerships and demographic trends drive long-term opportunity.Read more
611
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
US$114.5
62.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
26.56% p.a.
Profit Margin
16.15%
Future PE
142.25x
Price in 2029
US$138.3
Trending Discussion
Recently Updated Narratives
AN
NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening Adoption
Fair Value: US$130 66.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
GRAL: Future Returns Will Hinge On Upcoming NHS Trial Readout
Fair Value: US$114.5 62.4% undervalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GRAIL, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -10.12
- 48.46%
- -277.47%
- 0%
About GRAL
- Founded
- 2015
- Employees
- 1000
- CEO
- WebsiteView website
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
